| BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton's tyrosine kinase (BTK) inhibitor. |
businesswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| BeiGene to Present at the RBC Capital Markets Global Healthcare Conference |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. A. |
businesswire.com |
2025-05-13 10:01:00 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices + |
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Graham Corporation and Legal & General Group Plc are recommended as buys due to strong balance sheets, strategic growth, and favorable market conditions. Butterfly Network, Hudson Pacific Properties, and B&G Foods are rated as holds, with potential for growth but facing significant challenges and uncertainties. |
seekingalpha.com |
2025-05-12 17:05:26 |
Czytaj oryginał (ang.) |
| BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit |
BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown impressive revenue growth and market share gains, with significant potential for future expansion and revenue generation. Tevimbra, while facing intense competition, shows promise with recent FDA approvals and ongoing trials targeting various cancers. |
seekingalpha.com |
2025-05-08 13:24:42 |
Czytaj oryginał (ang.) |
| BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript |
BeiGene, Ltd. |
seekingalpha.com |
2025-05-07 18:04:09 |
Czytaj oryginał (ang.) |
| Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat |
BeiGene Ltd. ONC stock is trading lower after the company reported mixed first-quarter 2025 financial results on Wednesday. |
benzinga.com |
2025-05-07 15:01:26 |
Czytaj oryginał (ang.) |
| Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics |
The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-07 14:35:42 |
Czytaj oryginał (ang.) |
| BeiGene Announces First Quarter 2025 Financial Results and Business Updates |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025. “We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all line. |
businesswire.com |
2025-05-07 10:00:00 |
Czytaj oryginał (ang.) |
| U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR pe. |
businesswire.com |
2025-04-29 19:32:00 |
Czytaj oryginał (ang.) |
| BeiGene to Announce First Quarter 2025 Financial Results on May 7 |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investo. |
businesswire.com |
2025-04-17 10:01:00 |
Czytaj oryginał (ang.) |
| BeiGene initiated with an Outperform at RBC Capital |
RBC Capital initiated coverage of BeiGene with an Outperform rating and $312 price target. RBC sees a path to robust revenue growth driven by Brukinsa's market dominance and high-value follow-on assets in the hematology-oncology space, the analyst tells investors in a research note. BeiGene's oncology pipeline, proven R&D capabilities, and a fast to-execution mindset are key ingredients for the company's emerging position as a global oncology powerhouse that could drive market capitalization expansion, the firm says. |
https://thefly.com |
2025-04-07 10:15:12 |
Czytaj oryginał (ang.) |
| BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit |
BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. |
benzinga.com |
2025-04-03 15:19:58 |
Czytaj oryginał (ang.) |
| BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre. |
businesswire.com |
2025-04-03 10:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer |
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell l. |
businesswire.com |
2025-03-31 10:00:00 |
Czytaj oryginał (ang.) |
| China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer |
On Tuesday, BeiGene Ltd ONC announced FDA approval for Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). |
benzinga.com |
2025-03-04 10:37:25 |
Czytaj oryginał (ang.) |
| BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025 |
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with a 78% and 55% increase, positioning BeiGene for profitability. BeiGene announced a name change to BeOne Medicines, transitioning from historical losses to profitability, and potentially attracting new buyers. |
seekingalpha.com |
2025-02-28 16:00:00 |
Czytaj oryginał (ang.) |
| BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for BeiGene (ONC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-27 12:35:59 |
Czytaj oryginał (ang.) |
| BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript |
BeiGene, Ltd. (NASDAQ:ONC ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Dan Maller - Head, Investor Relations John Oyler - Co-Founder, Chairman & Chief Executive Officer Matt Shaulis - General Manager, North America Lai Wang - Global Head, R&D Aaron Rosenberg - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Sean Laaman - Morgan Stanley & Co. Andrew Berens - Leerink Partners Jessica Fye - JPMorgan Yigal Nochomovitz - Citigroup Reni Benjamin - Citizens JMP Ziyi Chen - Goldman Sachs & Co Operator Good day, everyone. |
seekingalpha.com |
2025-02-27 12:24:27 |
Czytaj oryginał (ang.) |
| BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024. “Our fourth quarter and full year results demonstrate our tremendous growth as a global oncology powerhouse, reinforced by the continued success of BRUKINSA and the development of one of the most prolific solid tumor pipeline. |
businesswire.com |
2025-02-27 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene to Present at Upcoming Investor Conferences |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 am ET; and Leerink Partners Global Biopharma Conference on Monday, March 10, 2025 at 1:00 pm ET Live webcasts of these events can be accessed. |
businesswire.com |
2025-02-25 08:01:00 |
Czytaj oryginał (ang.) |
| BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock? |
BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-02-21 06:26:07 |
Czytaj oryginał (ang.) |
| BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27 |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can b. |
businesswire.com |
2025-02-13 08:01:00 |
Czytaj oryginał (ang.) |
| TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose t. |
businesswire.com |
2024-12-27 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformati. |
businesswire.com |
2024-12-23 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, whi. |
businesswire.com |
2024-12-12 21:30:00 |
Czytaj oryginał (ang.) |
| BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in. |
businesswire.com |
2024-12-09 22:30:00 |
Czytaj oryginał (ang.) |
| BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL. |
businesswire.com |
2024-12-04 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company's R&D leadership team will provide an update on BeiGene's innovative portfolio and pipeline, focusing on key presentations at the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. Th. |
businesswire.com |
2024-12-02 08:01:00 |
Czytaj oryginał (ang.) |
| BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US |
BeiGene's TEVIMBRA was just approved by the European Commission. The drug is poised to enter the EU and just reached the US market in October. BeiGene's revenue per share has grown significantly, with TEVIMBRA and BRUKINSA poised to drive the company towards profitability within 12-18 months. Analysts project BeiGene's revenues to reach $4.64 billion next year. On projected profitability the company is a strong buy with a 12-month price target of $293/share. |
seekingalpha.com |
2024-12-01 11:00:00 |
Czytaj oryginał (ang.) |
| European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. “Patients diagnosed with advanced gastric and esophageal cancers confront. |
businesswire.com |
2024-11-27 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene to Present at Upcoming Investor Conferences |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi's Global Healthcare Conference on Thursday, December 5 at 9:30 a.m. ET The live webcasts of these events can be accessed from the investors. |
businesswire.com |
2024-11-26 08:01:00 |
Czytaj oryginał (ang.) |
| Labcorp CFO Glenn Eisenberg Announces Plans to Retire |
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. |
prnewswire.com |
2024-11-19 09:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of BRUKINSA® (zanubrutinib) in the U.S. Under the terms of the agreem. |
businesswire.com |
2024-11-19 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer |
SAN MATEO, Calif. & BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company's name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person,. |
businesswire.com |
2024-11-14 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2024. “Our exceptional third-quarter results underscore the Company's global oncology leadership driven by our unique R&D and clinical advantages as well as the tremendous launch trajectory of BRUKINSA,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “In the U.S., BRUKINSA, with. |
businesswire.com |
2024-11-12 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion |
BeiGene, Ltd.'s TEVIMBRA shows promise with label expansion in Europe for 1st-line gastro/gastroesophageal junction cancer and 1st-line esophageal squamous cell carcinoma. BRUKINSA, a BTK inhibitor, generated $637 million in sales in Q2 2024, which was a 107% year-over-year increase, showcasing its market potential. The company's Q2 2024 revenue hit $929 million, a 56% increase, but high R&D and G&A expenses necessitate potential financial instruments to be used within 12 months. |
seekingalpha.com |
2024-11-06 15:35:57 |
Czytaj oryginał (ang.) |
| BeiGene to Present at the Jefferies London Healthcare Conference |
SAN MATEO, Calif. and BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies London Healthcare Conference on November 20, 2024, with a fireside chat at 2:30 p.m. GMT. The live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available. |
businesswire.com |
2024-11-06 08:01:00 |
Czytaj oryginał (ang.) |
| BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton's tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation. “In the five years since its initial. |
businesswire.com |
2024-11-05 11:05:00 |
Czytaj oryginał (ang.) |
| BeiGene Mourns Death of Beloved Board Member Donald Glazer |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the passing of our dear friend, Don Glazer. He helped guide the founding of the company in 2010 and was an ardent supporter. |
businesswire.com |
2024-10-28 08:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab) in gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and esophageal squamous cell carcinoma (ESCC). In G/GEJ adenocarcinoma, the CHMP positive opinion is for TEVIMBR. |
businesswire.com |
2024-10-21 10:00:00 |
Czytaj oryginał (ang.) |
| BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024 |
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA® (zanubrutinib), Bruton tyrosine kinase (BTK) chimeric degradation activation compound (CDAC) degrader BGB-16673 and B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax in patients with Waldenström's macroglobulinemia at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM) Oct. 17-19 in Prag. |
businesswire.com |
2024-10-16 10:00:00 |
Czytaj oryginał (ang.) |
| BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? |
BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-07 10:05:14 |
Czytaj oryginał (ang.) |